Hansa Biopharma AB (CHIX:HNSAS) Short-Term Debt: kr300.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HNSAS Hansa Biopharma AB CHIX:HNSAS
43 GF Score
Price kr25.64
GF Value kr14.50
! 7 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Short-Term Debt?

Hansa Biopharma AB CHIX:HNSAS 43 Short-Term Debt is kr300.9 Mil as of Jun. 2026. GuruFocus rates CHIX:HNSAS with a GF Score™ of 43/100 and a GF Value™ of kr14.50. The stock has 7 warning signs investors should review.

Hansa Biopharma AB's Short-Term Debt for the quarter that ended in Jun. 2026 was kr300.9 Mil.

Hansa Biopharma AB's quarterly Short-Term Debt declined from Dec. 2025 (kr136.9 Mil) to Mar. 2026 (kr0.0 Mil) but then increased from Mar. 2026 (kr0.0 Mil) to Jun. 2026 (kr300.9 Mil).

Hansa Biopharma AB's annual Short-Term Debt stayed the same from Dec. 2023 (kr0.0 Mil) to Dec. 2024 (kr0.0 Mil) but then increased from Dec. 2024 (kr0.0 Mil) to Dec. 2025 (kr136.9 Mil).

Hansa Biopharma AB Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Hansa Biopharma AB Short-Term Debt Related Terms

Hansa Biopharma AB Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Short-Term Debt Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 136.87

Hansa Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.47 140.08 136.87 0.00 300.85
CHIX:HNSAS
43GF Score
Hansa Biopharma AB CHIX:HNSAS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of kr300.9 Mil mean?
Hansa Biopharma AB (CHIX:HNSAS) has a Short-Term Debt of kr300.9 Mil as of Jun. 2026.
Is Hansa Biopharma AB's Short-Term Debt too high?
Hansa Biopharma AB's current Short-Term Debt is kr300.9 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Short-Term Debt compare to VRTX and REGN?
Hansa Biopharma AB's Short-Term Debt of kr300.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Hansa Biopharma AB's current Short-Term Debt is kr300.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Short-Term Debt of kr300.9 Mil. The stock's GF Value™ is kr14.50, compared to a current price of kr25.64 — trading 76.8% above its estimated fair value. The current Short-Term Debt is kr300.9 Mil. Hansa Biopharma AB's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Short-Term Debt is kr300.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr25.64 is trading 76.8% above its estimated GF Value™ of kr14.50.

Key valuation signals for CHIX:HNSAS:

  • Short-Term Debt: kr300.9 Mil
  • GF Value™: kr14.50 vs. price of kr25.64 (76.8% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
43GF Score

Get the complete analysis for CHIX:HNSAS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.64
Price
kr14.50
GF Value